OakChart

Pulse Biosciences Inc

PLSEHealthcare·Medical Instruments & Supplies·USA·Mid·NASD·Nov 11 • 12:15 PM ET

56.44+1.32 (2.39%)
2026-11-11 18:15 CET
Market cap
4,054.02 USD m
Revenue, TTM
1.49 USD m
Net income, TTM
-83.72 USD m
Free cash flow, TTM
-63.70 USD m
EPS diluted, TTM
-1.21
P/E
-
Compare

Price

PLSE against its 20, 50 and 200-day averages
2050200beatearnings
20.0030.0040.0050.0060.00906K1.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLSEclose 56.4420-day 52.5550-day 51.94200-day 32.9756.4452w high

4.2% under the 52-week high of 58.94 on 9 Nov 2026. 52-week low 12.56 on 20 Nov 2025. Last 15 sessions, 17.9% high to low

Profile

PLSE
52-week range, 95% of the way up
12.5658.94

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

IndexRUT
Employees116
IPOMay 18, 2016
Beta1.64
ATR, 14d4.03
Rel volume0.35
Short float13.01%
Insider own69.70%
Inst own14.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.15B
Enterprise Value3.97B
Income-83.72M
Sales1.49M
Book/sh2.50
Cash/sh2.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees116
IPOMay 18, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S2785.84
P/B22.54
P/C21.94
P/FCF-
EV/EBITDA-
EV/Sales2663.13
Quick Ratio14.33
Current Ratio14.35
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.21
EPS next Y-1.25
EPS next Q-0.31
EPS this Y-52.03%
EPS next Y-9.05%
EPS next 5Y-15.03%
EPS past 3/5Y14.44% 12.82%
Sales past 3/5Y-20.63% -
EPS Y/Y TTM-6.34%
Sales Y/Y TTM1637.21%
EPS Q/Q-11.40%
Sales Q/Q359.30%
EarningsNov 05 AMC
EPS/Sales Surpr.21.65% -24.16%

Ownership

Insider Own69.70%
Insider Trans1.34%
Inst Own14.70%
Inst Trans28.72%
ROA-53.95%
ROE-60.61%
ROIC-44.49%
Gross Margin0.70%
Oper. Margin-5821.08%
Profit Margin-5603.88%
SMA207.41%
SMA508.65%
SMA20071.20%
Trades-

Technical

Shs Outstand73.31M
Shs Float22.29M
Short Float13.01%
Short Ratio5.72
Short Interest2.90M
52W High58.94 -4.25%
52W Low12.56 349.34%
Volatility11.86% 7.76%
ATR (14)4.03
RSI (14)57.15
Beta1.64
Rel Volume0.35
Avg Volume506.88K
Volume81,020

Performance

Perf Week-1.09%
Perf Month16.27%
Perf Quarter25.64%
Perf Half Y135.55%
Perf YTD311.05%
Perf Year268.39%
Perf 3Y993.74%
Perf 5Y161.53%
Perf 10Y839.05%
Recom1.00
Target Price67.67
Prev Close55.12
Price56.44
Change %2.39%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedBBTIG ResearchBuy$70+24.0%
Aug 17, 2026InitiatedNNeedhamBuy$58+2.8%
Jun 04, 2026InitiatedCCanaccord GenuityBuy$32-43.3%
Jan 30, 2026InitiatedMMizuhoOutperform$25-55.7%
Jul 07, 2025InitiatedOOppenheimerOutperform$22-61.0%
Jul 27, 2021InitiatedSStephensOverweight$28-50.4%
Mar 11, 2021InitiatedMMaxim GroupBuy$40-29.1%
Jan 26, 2021ReiteratedHH.C. WainwrightBuy$16 → $40-29.1%
May 12, 2020UpgradeHH.C. WainwrightNeutral → Buy$6 → $16-71.6%
Feb 14, 2020DowngradeHH.C. WainwrightBuy → Neutral$26 → $6-89.4%

Peers

Mkt cap
TickerCompanyMkt cap
ATRCAtricure Inc2.87B
ANGOAngiodynamic Inc509.28M
BSXBoston Scientific Corp65.78B
MDTMedtronic Plc129.27B
ABTAbbott Laboratories190.11B
STXSStereotaxis Inc87.02M
JNJJohnson & Johnson667.38B
IRTCiRhythm Holdings Inc2.97B
KMTSKestra Medical Technologies Ltd1.81B
NVCRNovoCure Ltd1.42B

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Teplitsky Liane RaeChief Operating OfficerSep 01 '26Buy49.951,00150,0004,095Sep 02 07:38 PM
Teplitsky Liane RaeChief Operating OfficerAug 31 '26Buy48.801,02449,9713,094Sep 02 07:38 PM
Teplitsky Liane RaeChief Operating OfficerAug 28 '26Buy48.351,03449,9942,070Aug 28 07:48 PM
Teplitsky Liane RaeChief Operating OfficerAug 26 '26Buy48.231,03649,9711,036Aug 28 07:48 PM
LAVIOLETTE PAUL AChief Executive OfficerMay 11 '26Buy19.6915,000295,35015,000May 11 06:53 PM
DUGGAN ROBERT WDirectorMay 11 '26Buy19.69660,23312,999,98848,211,433May 11 06:52 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Option Exercise1.535,0007,65048,298Feb 23 08:55 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Sale23.645,000118,20043,298Feb 23 08:55 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Option Exercise1.5320,00030,60063,298Feb 17 08:47 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Option Exercise1.5320,00030,60063,298Feb 17 08:47 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Option Exercise1.5320,00030,60063,298Feb 17 08:47 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Sale23.6320,000472,60043,298Feb 17 08:47 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Sale23.5320,000470,60043,298Feb 17 08:47 PM
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Sale23.3720,000467,40043,298Feb 17 08:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
PTHInvesco Dorsey Wright Healthcare Momentum ETFAUM: 291.00M
IWCiShares Micro-Cap ETFAUM: 1.22B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B

News

latest 14 of 206
  • Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting (Business Wire)
  • Pulse Biosciences Beats On EPS And Finishes Pivotal Enrollment Early, But CE Mark Timelines Slip And Spending Rises (Earnings Whispers) -6.99%
  • Pulse Biosciences to Present at Stifel 2026 Healthcare Conference (Business Wire)
  • Pulse Biosciences Must Confirm Its AFib Pivotal Trial Finished Early As Cash Burn Climbs (Earnings Whispers)
  • Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026 (Business Wire)
  • Loading…
  • Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center (Business Wire)
  • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.66%
  • Pulse Biosciences nPulse Technology to be Featured at the 21st Annual International VT Symposium 2026 (Business Wire)
  • Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment (Business Wire)
  • Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules (Business Wire)
  • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ... (GuruFocus.com) +10.90%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.243-0.310-0.3200.400.526
2026Q22026-08-06-0.285-0.310-0.3560.430.504
2026Q12026-05-04-0.238-0.270-0.2730.400.252
2025Q42026-02-19-0.183-0.265-0.2570.260.152
2025Q32025-11-05-0.203-0.310-0.2880.090.501
2025Q22025-08-12-0.199-0.260-0.2850.000.001
2025Q12025-05-08-0.170--0.2500.00--
2024Q42025-03-27-0.165--0.312-0.01--
2024Q32024-10-30-0.156--0.208-0.01--
2024Q22024-08-19-0.200--0.199-0.01--
2024Q12024-05-07-0.143--0.184-0.01--
2023Q42024-03-28-0.154--0.217-0.01--
2023Q32023-11-13-0.152-0.240-0.192--1
2023Q22023-08-10-0.220-0.240-0.223--1
2023Q12023-05-11-0.227-0.220-0.2620.000.001
2022Q42023-03-30-0.221-0.240-0.247-0.010.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.260-2.210-2.2640.000.00
2020FY-2.140-2.050-2.1440.000.00
2021FY-2.280-2.270-2.2771.421.45
2022FY-1.501-1.750-1.7240.700.71
2023FY-0.705--0.8790.70-
2024FY-0.635--0.9180.70-
2025FY-0.755-1.025-1.0800.350.15
2026FY--1.147--1.86
2027FY--1.251--4.56
2028FY--1.148--12.57
2029FY--1.007--49.20
2030FY--0.583--95.27

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-066040.600.400.82
2026Q4S2026-10-216010.700.400.82
2026Q4S2026-10-096020.700.400.82
2026Q4S2026-09-216010.820.401.50
2026Q4S2026-09-045010.860.401.50
2026Q4S2026-08-074010.880.401.50
2026Q4S2026-07-314000.930.401.50
2026Q4S2026-07-183000.970.401.50
2026Q4S2026-06-033010.970.401.50
2026Q4S2026-05-042011.251.001.50
2026Q4S2026-02-202101.301.001.60
2026Q4S2026-01-292001.251.001.50
2026Q4S2026-01-201001.501.501.50
2026Q4S2025-11-111011.501.501.50

Estimate history

EPS, annual-1.73-2.198-2.264-2.144-2.277-1.724-0.879-0.918-1.08-1.2072
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.208-0.312-0.25-0.285-0.288-0.257-0.273-0.356-0.321
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00001.4180.7000.351.49
Period201720182019202020212022202320242025TTM
Sales, quarterly00000.0860.2640.4010.4340.395
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.81920.59320.82525.5529.71637.23555.14465.92667.8473.315
Period201720182019202020212022202320242025MRQ
Shares, quarterly61.51665.92667.27467.27867.73867.8468.22570.873.315
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.490.350.000.000.701.420.000.000.00
Cost of Goods Sold Incl. D&A1.481.611.181.2113.283.111.091.161.31
Gross Profit0.01-1.26-1.18-1.21-12.58-1.70-1.09-1.16-1.31
Selling, General and Administrative Excl. Other86.9875.6853.1842.3745.4861.3248.8746.7936.65
Research and Development57.3444.7232.3427.8020.5628.6426.4424.9617.25
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-86.97-76.94-54.36-43.57-58.06-63.01-49.97-47.95-37.96
Interest Expense0.000.000.001.100.450.650.000.000.00
Unusual Expense0.000.001.900.000.000.000.00--
Net Income Before Taxes-83.72-72.78-53.59-42.21-58.51-63.66-49.85-46.97-37.55
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-83.72-72.78-53.59-42.21-58.51-63.66-49.85-46.97-37.55
Net Income From Continuing Operations-83.72-72.78-53.59-42.21-58.51-63.66-49.85-46.97-37.55
Net Income-83.72-72.78-53.59-42.21-58.51-63.66-49.85-46.97-37.55
EPS (Recurring)-1.16-1.08-0.89-0.88-1.72-2.28-2.14-2.26-2.20
EPS (Basic, Before Extraordinaries)-1.21-1.08-0.92-0.88-1.72-2.28-2.14-2.26-2.20
EPS (Diluted)-1.21-1.08-0.92-0.88-1.72-2.28-2.14-2.26-2.20
EBITDA-85.94-75.87-53.18-42.37-56.70-61.87-48.87-46.79-36.65
Non-Operating Income (Expense)3.254.162.672.460.000.000.110.980.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.1721.4613.597.185.1914.6010.0711.2912.34
Price To Sales Ratio2,403.422,643.82--134.29292.06---
Gross Margin0.70-360.00---1,797.29-119.61---
Operating Margin-5,821.08-21,982.57---8,293.86-4,443.86---
Net Margin-5,603.88-20,794.57---8,357.86-4,489.42---
Shares Outstanding73.3167.8465.9355.1437.2329.7225.5520.8220.59
Market Capitalization4,054.024,054.021,071.01673.26103.12438.84604.65278.77235.84

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.400.430.400.260.090.000.000.00
Cost of Goods Sold Incl. D&A0.320.270.370.520.540.270.280.29
Gross Profit0.070.160.03-0.26-0.45-0.27-0.28-0.29
Selling, General and Administrative Excl. Other24.3725.4319.1818.0019.9220.0117.7618.08
Research and Development16.8516.9812.5910.9311.3912.0910.3110.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-24.29-25.27-19.15-18.25-20.37-20.27-18.04-18.36
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.001.90
Net Income Before Taxes-23.05-24.66-18.58-17.43-19.39-19.17-16.80-19.39
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-23.05-24.66-18.58-17.43-19.39-19.17-16.80-19.39
Net Income From Continuing Operations-23.05-24.66-18.58-17.43-19.39-19.17-16.80-19.39
Net Income-23.05-24.66-18.58-17.43-19.39-19.17-16.80-19.39
EPS (Recurring)-0.32-0.36-0.27-0.26-0.29-0.28-0.25-0.29
EPS (Basic, Before Extraordinaries)-0.32-0.36-0.27-0.26-0.29-0.28-0.25-0.31
EPS (Diluted)-0.32-0.36-0.27-0.26-0.29-0.28-0.25-0.31
EBITDA-24.03-25.02-18.89-17.99-20.11-20.01-17.76-18.08
Non-Operating Income (Expense)1.240.610.570.820.981.111.250.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.314.971.914.975.625.195.686.79
Price To Sales Ratio2,403.421,619.341,954.732,659.2613,868.77---
Gross Margin18.6137.107.73-96.59-522.09---
Operating Margin-6,149.87-5,823.04-4,775.56-6,914.02-23,682.56---
Net Margin-5,835.70-5,681.34-4,633.67-6,603.41-22,540.70---
Shares Outstanding73.3170.8068.2367.8467.7467.2867.2765.93
Market Capitalization4,054.021,919.181,467.88930.451,191.141,015.16989.801,071.01

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments80.73118.0444.3761.1428.6120.4825.4059.5838.07
Short Term Receivables0.270.000.000.000.060.000.000.000.00
Inventories0.140.000.000.005.820.000.000.000.00
Other Current Assets2.281.410.961.012.131.861.000.780.41
Total Current Assets83.42119.4545.3362.1536.6322.3426.4060.3638.48
Net Property, Plant & Equipment7.068.328.7810.0211.2511.927.682.172.57
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets3.374.014.685.346.016.677.348.008.67
Deferred Tax Assets1.571.591.652.733.253.61---
Other Assets0.690.680.360.360.360.360.490.100.10
Total Assets96.11134.0660.8080.6057.5044.9141.9170.6449.82
Short Term Debt Incl. Current Port. of LT Debt1.571.351.061.811.210.540.000.000.00
Accounts Payable2.781.671.841.572.901.721.961.270.78
Other Current Liabilities3.587.033.812.604.415.332.501.841.43
Total Current Liabilities7.9210.056.715.988.527.584.463.112.21
Long Term Debt5.967.548.0974.1410.0410.816.720.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.571.591.652.733.253.61---
Other Liabilities0.000.000.000.000.000.000.001.201.61
Total Liabilities15.4619.1916.4482.8521.8122.0111.184.313.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity80.66114.8644.36-2.2535.6922.8930.7466.3345.99
Total Shareholders Equity80.66114.8644.36-2.2535.6922.8930.7466.3345.99
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity80.66114.8644.36-2.2535.6922.8930.7466.3345.99
Total Liabilities & Stockholders Equity96.11134.0660.8080.6057.5044.9141.9170.6449.82
Book Value Per Share1.191.740.80-0.061.200.901.483.222.73
Tangible Book Value Per Share1.141.680.72-0.201.000.631.122.832.22
Full-Time Employees11675566114295825433
Price to Book Ratio22.0113.5312.9116.6612.3326.639.093.567.72
Return on Assets-63.24-55.00-59.70-84.72-124.32-114.84-83.46-62.34-67.16
Return on Equity-74.45-67.31-200.47-349.89-217.33-185.90-96.78-66.85-71.72
Return on Invested Capital-84.03-43.78-80.48-81.37-139.21-147.89-125.40-56.60-55.59
Quick Ratio10.5111.886.7610.393.622.955.9219.4217.39
Current Ratio10.5311.886.7610.394.302.955.9219.4217.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-83.72-72.78-53.59-42.21-58.51-63.66-49.85-46.97-37.55
Depreciation1.031.071.181.211.351.151.091.161.31
Other Funds (Non Cash)18.5222.6113.597.1913.8514.6110.1910.7712.20
Funds from Operations-64.17-49.10-38.81-33.81-43.30-47.90-38.56-35.05-24.01
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.84-5.022.470.77-3.72-6.203.200.860.11
Cash from Operating Activities-63.33-54.12-36.34-33.04-47.01-54.10-35.37-34.19-23.90
Capital Expenditures-0.37-0.34-0.12-0.12-0.40-0.44-0.44-0.61-0.28
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-152.350.000.000.000.008.0010.48-9.4926.39
Purchase of Investments-152.350.000.000.000.000.00-29.02-77.99-40.30
Sale Or Maturity of Investments0.000.000.000.000.008.0039.5168.5066.69
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-152.72-0.34-0.12-0.12-0.407.5610.04-10.1026.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock157.5617.15110.1416.3915.3862.5130.890.6945.61
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock157.5617.15110.1416.3915.3862.5130.890.6945.61
Proceedsfrom Stock Options142.740.5959.850.4015.3557.5129.920.4244.79
Issuance or Reduction of Debt, Net0.000.000.000.0064.560.410.000.000.00
Change in Long Term Debt0.000.000.000.0064.560.410.000.000.00
Issuance of Long Term Debt0.000.000.000.0065.001.940.000.000.00
Reduction of Long Term Debt0.000.000.000.00-0.44-1.530.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.230.00-0.61-0.12
Other Financing Activities Uses0.000.000.000.000.00-0.230.00-0.61-0.12
Cash from Financing Activities157.5617.15110.1416.3979.9462.6930.890.0845.50
Net Change in Cash-58.49-37.3073.67-16.7732.5216.155.56-44.2047.72
Free Cash Flow-63.70-54.44-36.47-33.16-47.41-54.53-35.81-34.79-24.17
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.03

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments189.19101.6268.3280.7395.21106.35
Short Term Receivables0.500.120.160.270.010.00
Inventories0.230.240.210.140.060.05
Other Current Assets2.293.722.452.281.871.76
Total Current Assets192.21105.7071.1383.4297.16108.16
Net Property, Plant & Equipment6.136.456.727.067.377.72
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.853.013.203.373.533.70
Deferred Tax Assets---1.57--
Other Assets0.400.400.570.690.700.68
Total Assets201.58115.5681.6296.11108.77120.25
Short Term Debt Incl. Current Port. of LT Debt1.751.691.631.571.521.46
Accounts Payable3.022.832.762.782.982.74
Other Current Liabilities8.636.465.413.585.204.78
Total Current Liabilities13.3910.989.807.929.708.98
Long Term Debt4.625.095.535.966.376.79
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.57--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities18.0116.0615.3215.4616.0715.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity183.5799.5066.3080.6692.69104.49
Total Shareholders Equity183.5799.5066.3080.6692.69104.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity183.5799.5066.3080.6692.69104.49
Total Liabilities & Stockholders Equity201.58115.5681.6296.11108.77120.25
Book Value Per Share2.501.410.971.191.371.55
Tangible Book Value Per Share2.471.360.921.141.321.50
Full-Time Employees---116--
Price to Book Ratio22.0128.5418.1610.0311.408.57
Return on Assets-53.95-67.90-69.36-63.24-74.06-84.68
Return on Equity-60.61-78.49-80.72-74.45-86.99-103.50
Return on Invested Capital-12.25-23.58-25.87-20.13-19.57-17.23
Quick Ratio14.339.617.2410.5110.0112.04
Current Ratio14.359.637.2610.5310.0212.05

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-23.05-24.66-18.58-17.43-19.39-19.17
Depreciation0.260.250.260.260.260.27
Other Funds (Non Cash)5.385.302.565.285.915.75
Funds from Operations-17.41-19.10-15.76-11.90-13.22-13.15
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.140.391.17-2.860.180.34
Cash from Operating Activities-15.27-18.71-14.60-14.76-13.04-12.81
Capital Expenditures-0.14-0.09-0.03-0.10-0.06-0.12
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-152.350.000.000.000.000.00
Purchase of Investments-152.350.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-152.49-0.09-0.03-0.10-0.06-0.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock102.8752.102.210.381.970.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock102.8752.102.210.381.970.00
Proceedsfrom Stock Options96.3546.45-0.06-0.010.240.35
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities102.8752.102.210.381.970.00
Net Change in Cash-64.8933.30-12.42-14.48-11.13-12.93
Free Cash Flow-15.41-18.80-14.63-14.86-13.10-12.91

Revenue breakdown

Total Surgical & Medical Instruments & Apparatus revenue2025: 350.00K
United States2025: 350.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.01%2.9M22.3M500.08K
2026-10-1513.64%3.0M22.0M514.40K
2026-09-3015.74%3.3M21.1M488.75K
2026-09-1514.92%3.1M21.1M460.85K
2026-08-3116.34%3.1M19.1M381.87K
2026-08-1414.47%2.8M19.1M369.94K
2026-07-3115.61%3.0M19.1M372.71K
2026-07-1515.59%2.9M18.5M339.04K
2026-06-3015.46%2.9M18.5M340.38K
2026-06-1515.25%2.8M18.5M309.05K
2026-05-2917.57%3.1M17.6M300.16K
2026-05-1518.32%3.2M17.6M321.96K
2026-04-3016.25%2.9M18.0M363.40K
2026-04-1516.32%2.9M17.8M348.75K
2026-03-3116.51%2.9M17.7M336.28K
2026-03-1314.85%2.6M17.7M325.81K
2026-02-2714.34%2.5M17.7M304.63K
2026-02-1314.33%2.5M17.7M270.52K
2026-01-3014.89%2.6M17.6M174.83K
2026-01-1514.61%2.6M17.6M170.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0019.0023.9014.003.4931.000.000.888-0.2970.017
call37.0017.0021.900.003.1980.000.000.877-0.2890.018
call38.0016.0020.900.003.0570.000.000.872-0.2850.019
call39.0015.0019.900.002.8640.000.000.866-0.2810.019
call40.0014.0018.9013.152.81517.000.000.859-0.2760.020
call41.0013.0017.800.002.5540.000.000.853-0.2720.020
call42.0012.0016.800.002.4260.000.000.846-0.2660.021
call43.0011.0015.800.002.3480.000.000.837-0.2600.022
call44.0010.0014.800.002.2230.000.000.828-0.2540.023
call45.009.0013.8011.002.0998.000.000.819-0.2480.023
call46.008.0012.800.001.9773.000.000.808-0.2410.024
call47.007.0011.800.001.8560.000.000.797-0.2340.025
call48.006.5011.207.251.8099.000.000.784-0.2260.026
call49.005.5010.305.901.7576.000.000.770-0.2170.027
call50.004.509.300.001.6350.000.000.756-0.2090.028
call55.000.504.904.951.19734.000.000.589-0.2800.034
call60.000.252.500.011.1137.001.000.402-0.2230.034
call65.000.004.901.501.6135.000.000.313-0.2780.031
call70.000.004.900.001.9690.000.000.275-0.3170.029
call75.000.004.900.002.1720.000.000.254-0.3440.028
call80.000.004.900.002.5180.000.000.234-0.3720.027
put35.000.004.900.003.0580.000.00-0.116-0.2870.017
put37.000.004.900.002.7890.000.00-0.128-0.2790.018
put38.000.004.900.002.7510.000.00-0.127-0.2820.019
put39.000.004.900.002.5260.000.00-0.140-0.2690.019
put40.000.004.900.002.4370.000.00-0.144-0.2670.020
put41.000.004.900.002.2760.000.00-0.154-0.2590.021
put42.000.004.900.002.1540.000.00-0.162-0.2530.021
put43.000.004.900.002.1190.000.00-0.163-0.2550.022
put44.000.004.900.001.8880.000.00-0.184-0.2380.023
put45.000.004.904.121.77010.000.00-0.195-0.2310.024
put46.000.004.900.001.7320.000.00-0.196-0.2320.024
put47.000.004.900.001.6480.000.00-0.204-0.2270.025
put48.000.004.900.001.5320.000.00-0.217-0.2190.026
put49.000.004.902.951.44925.000.00-0.227-0.2140.027
put50.000.001.902.481.15644.000.00-0.271-0.1760.030
put55.000.504.902.701.5927.000.00-0.414-0.2730.034
put60.003.707.000.001.3950.000.00-0.594-0.2160.034
put65.008.1011.000.001.5070.000.00-0.680-0.2650.032
put70.0011.6016.000.002.0220.000.00-0.720-0.3040.030
put75.0016.5021.000.002.1180.000.00-0.746-0.3360.028
put80.0021.5026.000.002.4750.000.00-0.764-0.3600.027

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-06SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-078-KCurrent report2026-10-07SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-15424B5SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-04-08SEC
2026-08-283Initial statement of beneficial ownership of securities2026-04-08SEC
2026-08-284Statement of changes in beneficial ownership of securities2025-02-03SEC
2026-08-283Initial statement of beneficial ownership of securities2025-02-03SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06424B5SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-05-154/A2026-05-11SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-13SCHEDULE 13D/ASEC
2026-05-114/A2026-05-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0950.00K100
2026-08149.94K300
2026-070000
2026-060000
2026-0513.30M200
2026-040000
2026-030000
2026-02002.93M7
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.2.12%
BANK OF AMERICA CORP /DE/2.09%
VANGUARD CAPITAL MANAGEMENT LLC1.14%
Portolan Capital Management, LLC1.09%
PRICE T ROWE ASSOCIATES INC /MD/1.08%
BALYASNY ASSET MANAGEMENT L.P.1.04%
CITADEL ADVISORS LLC0.91%
STATE STREET CORP0.77%
GEODE CAPITAL MANAGEMENT, LLC0.75%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/0.67%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.80%
iShares Russell 2000 ETF0.70%
T. Rowe Price New Horizons Fund, Inc.0.70%
Strategic Advisers U.S. Total Stock Fund0.48%
MFS New Discovery Fund0.48%
VANGUARD EXTENDED MARKET INDEX FUND0.31%
Fidelity Small Cap Index Fund0.30%
iShares Russell 2000 Growth ETF0.25%
MFS New Discovery Series0.18%
VANGUARD RUSSELL 2000 INDEX FUND0.15%

OakChart. PLSE. Cached 15 minutes.